Antengene Team Standing Out as a Leader in Innovation and Entrepreneurship

Feb 13, 2019View PDF


SHANGHAI and SHAOXING, China, Feb 13, 2019—Recently, the Science and Technology Department of Zhejiang Province announced the list of “2018 leading teams in innovation and entrepreneurship in Zhejiang Province”. Antengene Corporation is shortlisted in virtue of its “Pioneering Team in First Categoty New Oncology Drug Clinical Development and Its Industrialization”. Antengene, therefore, demonstrates its capabilities in R&D and commercialization.

A total of 8 leading teams in entrepreneurship in Zhejiang Province are finally listed, which will receive financial subsidies from provincial and municipal governments, enjoy the government’s preference to gain more supports for R&B, and also win extra bonus point in platform evaluation and talent recommendation.

Dr. Jay Mei , head of Antengene’s leading team in entrepreneurship, founder and chairman of Antengene Corporation, says, “this is the highest level of group project in Zhejiang Province, which means stricter requirements in application and greater difficulty to be selected. Although it is the first time for young Antengene to declare, our team is strong lineup with rich experience in innovation. Led by a number of scientists at home and abroad, our team stands out after the repeated siftings of Science and Technology Department and Organization Department of Zhejiang Province. It attests perfectly to our strength in technology R&D and commercialization. Taking this as an opportunity, we continue to build a world-class team in drug R&D, remain rigorous to develop with the scientific spirit and provide patient-oriented services. At the same time, we will actively promote the commercialization of drugs so that clinical drugs against life-threatening diseases will be available to patients in China and other Asia-Pacific countries.”

About “Leading Team in Innovation and Entrepreneurship in Zhejiang Province”
It refers to an excellent group with its own technology, projects and capitals launching the business in Zhejiang Province. The team should have a clear product layout and good market prospects, keep in line with the local industrial development strategy and technological innovation demands, and stand ready to lead the industrial innovation and development of Zhejiang Province. Science and technology are the primary productive forces, and talent is the decisive resource. Technically, talent is the most critical factor in scientific and technological innovation. In recent years, CPC Municipal Committee and People’s government of Zhejiang Province have attached great importance to scientific and technological innovation, accelerated the construction of provincial key innovation teams, and increased the support for the cultivation of teams in innovation and entrepreneurship.

About Antengene

Antengene Corporation is a biopharmaceutical company focused on drug discovery, clinical development and the commercialization of innovative therapeutics to meet unmet medical needs. Antengene aims to provide the most advanced and first-in-class anti-cancer drug treatments for patients around the world. On April 13, 2017, Celgene Corporation (NASDAQ: CELG), a global leading innovative biopharmaceutical company became a long-term strategic partner and obtained an equity position in Antengene. Antengene’s pipeline includes six commercial and clinical stage products: ATG-010 (selinexor), in combination with the corticosteroid dexamethasone, has been approved by the U.S. Food and Drug Administration, for the treatment of adult patients with relapsed or refractory multiple myeloma. The compound is also in late clinical development for various other hematologic malignancies and solid tumors. ATG-008, a second-generation dual mTORC1/2 inhibitor, is in a multi-regional clinical trial for treatment of hepatocellular carcinoma and multiple other solid tumors. Two other Phase 1 and Phase 2 clinical stage drugs, ATG-016 and ATG-019, are being studied in multiple cancer types, including MDS, colorectal and prostate cancers. ATG-527 is being explored for multiple anti-viral indications, including respiratory syncytial virus (RSV), and Epstein-Barr virus (EBV) related diseases, etc. ATG-017 is a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 (ERK1/2) inhibitor, in clinical development for multiple solid tumors. Antengene drug discovery team focuses on development of first-in-class novel products.